Patents Examined by Leonard Schenkman
  • Patent number: 5955475
    Abstract: Solid dispersions of poorly soluble drugs are disclosed which are prepared using a solvent or fusion process. Such dispersions are manufactured with the free base of the drug, specifically paroxetine free base, an oil, allowing for a low temperature for the fusion process, decreased organic solvent volumes for the solvent process and the formation of a paroxetine salt during the solid dispersion manufacture process.
    Type: Grant
    Filed: June 30, 1997
    Date of Patent: September 21, 1999
    Assignee: Endo Pharmaceuticals Inc.
    Inventors: Philip J. Krape, Sou-Chan Chang, William A. Hein, II, Christopher A. Teleha
  • Patent number: 5929039
    Abstract: The present invention relates generally to a method for, and pharmaceutical compositions useful in, the prophylaxis and/or treatment of cardiac dysfunction in a mammal by the administration of an effective amount of an agent capable of blocking or inhibiting the effect or release of inositol(1,4,5)trisphosphate in cardiac tissue.
    Type: Grant
    Filed: August 5, 1996
    Date of Patent: July 27, 1999
    Assignee: Baker Medical Research Institute
    Inventors: Elizabeth Anne Woodcock, Karen Elizabeth Anderson, Anthony Michael Dart, Xiao-Jun Du
  • Patent number: 5925647
    Abstract: Novel cryptolepine analogs useful as hypoglycemic agents and methods for their use as hypoglycemic agents, for example, in the treatment of diabetes, and a method for their synthesis are described. As hypoglycemic agents, the novel cryptolepine analogs are useful for the treatment of insulin-dependent diabetes mellitus (IDDM or Type I) and non-insulin dependent diabetes mellitus (NIDDM or Type II).
    Type: Grant
    Filed: October 20, 1997
    Date of Patent: July 20, 1999
    Assignee: Shaman Pharmaceuticals, Inc.
    Inventor: Donald E. Bierer
  • Patent number: 5910493
    Abstract: The pharmaceutical composition, especially for treating skin with seborrhea, Acne vulgaris and androgonically conditioned alopecia, contains a hormonal agent including the gestogen, dienogest, or a combination of dienogest and an estrogen, as active ingredient. Methods for treatment of this type of skin condition include topical application of the composition including the dienogest which results in an outstanding sebosuppression, a drastic reduction of androstandiol glucuronide and a moderate competitive blockage of androgen receptor sites. Galenic formulations are described which limit and/or prevent the permeation of the active ingredient through the skin.
    Type: Grant
    Filed: September 16, 1996
    Date of Patent: June 8, 1999
    Assignee: Jenapharm GmbH
    Inventors: Siegfried Golbs, Michael Oettel, Michael Dittgen, Thomas Graser, Christoph Luderschmidt
  • Patent number: 5906978
    Abstract: The invention relates to methods and compositions for delivering iron to an iron-deficient patient, more particularly, to methods whereby an iron complex comprising divalent or trivalent ionic iron complexed with one or more low molecular weight anions is administered to a patient by transfer from dialysate. A complex selected according to the invention is non-polymeric; soluble in an aqueous medium; chemically stable, thereby preventing the dissociation of iron ions from the anions under conditions according to the invention; and can be well absorbed into blood and the living body. Also provided are dialysate compositions including therein an iron complex selected according to the invention, and dialysate concentrates which may be diluted to yield an inventive dialysate composition.
    Type: Grant
    Filed: June 5, 1997
    Date of Patent: May 25, 1999
    Assignee: Hemocleanse, Inc.
    Inventor: Stephen R. Ash
  • Patent number: 5904929
    Abstract: A pharmaceutical composition for trans-mucosal or transdermal administration wherein a per-C.sub.2-18 acylated cyclodextrin is used as a drug reservoir or carrier. The composition can be used safely and exhibits excellent drug release behavior.
    Type: Grant
    Filed: July 2, 1997
    Date of Patent: May 18, 1999
    Assignee: Janssen Pharmaceutica, N.V.
    Inventors: Kaneto Uekama, Fumitoshi Hirayama, Akira Kondo, Masaaki Ohta, Yasuhiro Okamoto, Haruo Kunihiro
  • Patent number: 5902827
    Abstract: Substituted indenyl sulfonyl acetic acids, esters and alcohols are useful in the treatment of psoriasis.
    Type: Grant
    Filed: April 17, 1998
    Date of Patent: May 11, 1999
    Assignee: Cell Pathways
    Inventors: Rifat Pamukcu, Gary Piazza, Ewa Skopinska-Rozewska
  • Patent number: 5900240
    Abstract: An edible composition comprising a mixture of at least two herbs selected from the group consisting of Syzygium cumini, Gymnema sylvestre, Momordica charantia and Solanum melongena. Preferably, the composition comprises a mixture of Syzygium cumini and Momordica charantia. A mixture of Syzygium cumini, Gymnema sylvestre and Momordica charantia is particularly preferred. The herbal mixtures are useful as dietary supplements and are especially useful for lowering the glucose level of the blood in mammals, particularly humans suffering from diabetes mellitus.
    Type: Grant
    Filed: March 6, 1998
    Date of Patent: May 4, 1999
    Assignee: Cromak Research, Inc.
    Inventors: Onkar S. Tomer, Peter Glomski, Kripanath Borah
  • Patent number: 5897865
    Abstract: The present invention relates to the administration of an effective amount of turmeric for the treatment of various health ailments and also as a food supplement to promote health and vitality. The turmeric is especially useful for the treatment of skin disorders, such as acne, when administered orally. It can also be used to treat liver and stomach disorders, skin discoloration, constipation, and hemorrhoids.
    Type: Grant
    Filed: June 30, 1997
    Date of Patent: April 27, 1999
    Inventor: Van Bich Nguyen
  • Patent number: 5889040
    Abstract: The present invention is based in part upon the discovery that the use of pyruvate in enteral formulations, in combination with an anabolic protein composition, produces a synergistic effect in increasing the lean body mass or muscle tissue of a mammal consuming same. The present invention also provides a method for enhanced endurance of athletes.The present invention relates generally to a composition for enhancing the protein concentration or muscle mass of a mammal and a method for enhancing the protein concentration or muscle mass in a mammal. More specifically, the present invention relates to a composition which comprises pyruvate and/or derivatives of pyruvate and an anabolic protein composition. The method of the present invention comprises administering to a mammal in need of enhancing its protein concentration or muscle mass, a composition comprising pyruvate and an anabolic protein composition.
    Type: Grant
    Filed: October 16, 1997
    Date of Patent: March 30, 1999
    Assignee: Paxton K. Beale
    Inventors: Paxton K. Beale, Donald O. Nickey
  • Patent number: 5889062
    Abstract: Topical formulations having a content of one compound or several compounds from the group consisting of ubiquinones and derivatives thereof in combination with a content of one compound or several compounds from the group consisting of plastoquinones and derivatives thereof or formulations having a content of one compound or several compounds from the group consisting of plastoquinones and derivatives thereof.
    Type: Grant
    Filed: December 24, 1996
    Date of Patent: March 30, 1999
    Assignee: Beiersdorf AG
    Inventors: Udo Hoppe, Gerhard Sauermann, Volker Schreiner, Klaus-Michael Steiger
  • Patent number: 5889051
    Abstract: A stable solid dispersion of prostaglandin drug, particularly Misoprostol, (.+-.)methyl 7-?3(.alpha.)-hydroxy-2-.beta.-(4 (RS)-4-hydroxy-4-methyl-trans-1-octen-1-yl)-oxycyclopent-1.alpha.-yl!hepta noate, comprising ammonio methacrylate copolymers. The ammonio methacrylate copolymers comprise Eudragit RS series, Eudragit RL series, Eudragit S, Eudragit L, and the mixture thereof. The stable solid dispersion is a sustained release type.
    Type: Grant
    Filed: July 15, 1997
    Date of Patent: March 30, 1999
    Assignee: Development Center for Biotechnology
    Inventors: David Chen, Rong-Jer Tsay, Hue-In Lin, Shu-Bin Lu
  • Patent number: 5886038
    Abstract: A pharmaceutical composition for use in the treatment of psoriasis, having isopropyl myristate as its only active ingredient.
    Type: Grant
    Filed: March 24, 1998
    Date of Patent: March 23, 1999
    Assignees: Panda Pharmaceuticals, L.L.C., The University of Tennessee Research Corporation
    Inventors: Thomas M. Glenn, E. William Rosenberg, Robert B. Skinner, Jr., Patricia W. Noah
  • Patent number: 5882688
    Abstract: A composition to be applied in the preservation of edible sea products exposed to melanization is disclosed; said composition being composed of potassium or sodium bisulfite, organic acids acceptable from the alimentary point of view, such as citric acid or tartaric acid and acid salts of the same, ascorbic acid or its salts and L-cysteine or N-acetyl-cysteine as an enzymatic inhibitor, antioxidant, sequestrate.
    Type: Grant
    Filed: April 11, 1997
    Date of Patent: March 16, 1999
    Assignee: Adital, S.A.
    Inventors: Eduardo G. Alonso, Normando Rogert, Salvador P. Florio, Hector E. Panzarasa
  • Patent number: 5883083
    Abstract: A dietary supplement for canines and felines includes taurine in a liquid lecithin base. The dietary supplement has proven effective in reducing epileptic seizures in canines and in reducing behavioral problems, such as aggression, in canines. In addition, the dietary supplement is more easily digestible than conventional tablet forms of taurine and is more effectively administered to felines for treatment of cardiomyopathy.
    Type: Grant
    Filed: June 9, 1997
    Date of Patent: March 16, 1999
    Assignee: Harlmen, Inc.
    Inventor: Stanely James Harless
  • Patent number: 5879684
    Abstract: A skin tightening aqueous gel formed from the combination of water, a dispersed finely particulate vegetable based tautening or tensor agent, a polymeric gelling agent, a liquid hydrocarbon dispersing aid and a nonionic surfactant.There is described a method of dispensing and spreading the gel onto skin areas for the tightening treatment.
    Type: Grant
    Filed: April 11, 1997
    Date of Patent: March 9, 1999
    Assignee: Hydron Technologies, Inc.
    Inventor: Charles Fox
  • Patent number: 5877171
    Abstract: The method of this invention is directed to a treatment of depression in men and women and to a treatment of pre-menstrual syndrome (PMS) in women by administering to a patient a therapeutically effective amount of chromium in a pharmaceutically acceptable form either alone or in conjunction with the administration of a standard antidepressant composition, such as a selective serotonin reuptake inhibitor composition. Chromium, preferably in the form of chromium picolinate, is administered to the patient at dosages in a preferred range of about 200 to about 500 micrograms chromium.
    Type: Grant
    Filed: July 28, 1997
    Date of Patent: March 2, 1999
    Inventor: Malcolm N. McLeod
  • Patent number: 5874453
    Abstract: Compositions comprising a mixture of 2-(thiocyanomethylthio)benzothiazole and methylene-bis(thiocyanate) with dimethylamide of a carboxylic acid are disclosed which are synergistically effective compared to the respective components alone in controlling the growth of microorganisms in or on a product, material, or medium. Methods to control the growth of microorganisms and prevent spoilage caused by microorganisms with the use of the compositions of the present invention are also disclosed.
    Type: Grant
    Filed: July 11, 1997
    Date of Patent: February 23, 1999
    Assignee: Buckman Laboratories International, inc.
    Inventors: David Oppong, Vanja M. King
  • Patent number: 5872143
    Abstract: A pre-mix insecticidal composition is disclosed that contains (a) 0.1-10% by weight of 2,4-dioxo-1-(2-propynyl)imidazolidin-3-ylmethyl chrysanthemate, (b) 2.5-50% by weight of a fatty acid ester of 16-19 carbon atoms; (c) 2.5-30% by weight of a sorbitan fatty acid ester; (d) 0.5-1% by weight of at least one alcohol selected from the group consisting of ethanol, 1-propanol, 2-propanol, ethylene glycol, diethylene glycol, triethylene glycol, propylene glycol, dipropylene glycol, butylene glycol and glycerin; and (e) 40-93.5% by weight of a saturated hydrocarbon of 8-18 carbon atoms. This pre-mix insecticidal composition exhibits little, if any, precipitation when left to stand. It is sufficiently stable to be transported and is storage stable prior to formulating an insecticidal aerosol composition. A useful insecticidal aerosol composition contains 5-30% by weight of this pre-mix insecticidal composition, 40-85% by weight of water and 10-50% by weight of a propellant. The aerosol composition is stable, i.e.
    Type: Grant
    Filed: August 6, 1997
    Date of Patent: February 16, 1999
    Assignee: Sumitomo Chemical Company, Limited
    Inventors: Yasuyori Tanaka, Tadahiro Matsunaga
  • Patent number: 5869479
    Abstract: Relief from the symptoms of rhinitis is obtained by treatment with: (a) an antihistaminic effective amount of a histamine H.sub.1 receptor antagonist; together with (b) a sufficient amount of a histamine H.sub.3 receptor antagonist to provide a nasal decongestant effect. The components may be administered together in a single dosage form, or separately in the same or different dosage forms to maintain therapeutic systemic levels of both components.
    Type: Grant
    Filed: August 14, 1997
    Date of Patent: February 9, 1999
    Assignee: Schering Corporation
    Inventors: William Kreutner, John A. Hey